# Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

> **NCT00660179** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 742 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** macitentan (ACT-064992)
- **DRUG:** macitentan (ACT-064992)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00660179
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2012-03
- **Final completion:** 2012-04
- **Target enrollment:** 742 (ACTUAL)
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660179, "Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00660179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*